Founded in December 2017，We are a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutic candidates to treat cancer and Nephropathy.

Headquarter&Translation Medicine Center
Wuxi

R&D Center
Shanghai

North China Operation Center
Shijiazhuang&Beijing

South China Operation Center
Guangzhou

Central China Operation Center
Wuhan

Strategy

            Joint R&D for potential BIC pipeline
          
            2017-12-28
          
            Building a leading edge in the clinical trial system
          
            Enhancing in-house R&D capabilities and Transforming to Global Innovation
          
            Integrate resources to strengthen commercialization capabilities

News

19 2024.04

10 2024.04

BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3（GPC3）

03 2024.03

BioCity Announces Enrollment Completion of the IgA Nephropathy (IgAN) Cohort in the Randomized, Placebo-controlled Phase II Clinical Trial of the ETA Receptor Antagonist SC0062

Career

We have always been adhering to the mission of "Better Medicine for Better Life", and dedicate to developing "BIC/FIC" drugs with unmet needs.
We invite like-minded you to join us to create a healing tomorrow together.

Join Us